HeartBeam (BEAT) Net Income towards Common Stockholders (2020 - 2026)
HeartBeam's (BEAT) quarterly Net Income towards Common Stockholders came in at -$5.0 million in Q2 2026, down 1.31% year-over-year from -$5.1 million in Q2 2025, and down 7.21% quarter-over-quarter from -$4.7 million in Q1 2026.
Powered by 
Analysis
HeartBeam (BEAT) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
HeartBeam (BEAT) has reported Net Income towards Common Stockholders for 7 consecutive years, with -$5.0 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Net Income towards Common Stockholders fell 1.31% year-over-year to -$5.0 million in Q2 2026; TTM through Jun 2026 was -$15.9 million, a 2.22% increase from a year earlier, with the FY2025 full-year figure at -$16.6 million, down 8.17% from the prior year.
- Net Income towards Common Stockholders was -$5.0 million for Q2 2026 at HeartBeam, down from -$4.7 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$807000.0 in Q4 2024 and troughed at -$5.5 million in Q1 2025.
- A 5-year average of -$3.8 million and a median of -$4.0 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Across the five-year window, Net Income towards Common Stockholders tumbled 921.9% in 2022 and soared 79.2% in 2024, its largest moves.
- Over 5 years, Net Income towards Common Stockholders stood at -$3.7 million in 2022, then dropped by 4.5% to -$3.9 million in 2023, then soared by 79.2% to -$807000.0 in 2024, then retreated by 10.21% to -$889400.0 in 2025, then slumped by 466.56% to -$5.0 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$5.0 million (Q2 2026), -$4.7 million (Q1 2026), and -$889400.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 187.42 Bn | 182.47 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Intuitive Surgical | 129.78 Bn | 124.69 Bn | 1.96 Bn | 823.20 Mn |
| 3 | Medtronic | 120.53 Bn | 112.33 Bn | 6.34 Bn | 1.48 Bn |
| 4 | Stryker | 116.28 Bn | 112.80 Bn | 4.50 Bn | 1.28 Bn |
| 5 | Boston Scientific | 69.29 Bn | 68.99 Bn | 3.85 Bn | 907.00 Mn |
| 6 | Edwards Lifesciences | 51.83 Bn | 47.68 Bn | 1.35 Bn | 241.40 Mn |
| 7 | Alcon | 34.36 Bn | 32.91 Bn | 1.68 Bn | - |
| 8 | Dexcom | 33.17 Bn | 31.23 Bn | 830.00 Mn | 249.10 Mn |
| 9 | Resmed | 32.94 Bn | 31.47 Bn | 861.22 Mn | 383.43 Mn |
| 10 | HeartBeam | 24.23 Mn | 24.23 Mn | - | -5.04 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -5.04 Mn |
| Mar 31, 2026 | -4.70 Mn |
| Dec 31, 2025 | -889,400.00 |
| Sep 30, 2025 | -5.26 Mn |
| Jun 30, 2025 | -4.97 Mn |
| Mar 31, 2025 | -5.48 Mn |
| Dec 31, 2024 | -807,000.00 |
| Sep 30, 2024 | -4.98 Mn |
| Jun 30, 2024 | -4.96 Mn |
| Mar 31, 2024 | -4.61 Mn |
| Dec 31, 2023 | -3.88 Mn |
| Sep 30, 2023 | -3.47 Mn |
| Jun 30, 2023 | -3.15 Mn |
| Mar 31, 2023 | -4.14 Mn |
| Dec 31, 2022 | -3.71 Mn |
| Sep 30, 2022 | -3.58 Mn |
| Jun 30, 2022 | -3.53 Mn |
| Mar 31, 2022 | -2.15 Mn |
| Dec 31, 2021 | -2.09 Mn |
| Sep 30, 2021 | -1.19 Mn |